A. Puime-Otin

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

A. Cebrián, F. Rojo, M. Soengas, 2014, BMC Cancer.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

C. Nadal, F. Rojo, R. López-López, 2019, Scientific Reports.

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

A. Cebrián, M. Soengas, J. García-Foncillas, 2018, BMC Cancer.

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept

F. Gebauer, A. Cebrián, J. García-Foncillas, 2017, PloS one.

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

A. Cebrián, M. Soengas, J. García-Foncillas, 2018, BMC Cancer.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

A. Cebrián, C. Nadal, F. Rojo, 2019, Scientific Reports.